According to Dr Lal PathLabs 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 67.0204. At the end of 2022 the company had a P/E ratio of 76.9.
Year | P/E ratio | Change |
---|---|---|
2022 | 76.9 | -10.74% |
2021 | 86.1 | 8.96% |
2020 | 79.0 | 54.36% |
2019 | 51.2 | 31.38% |
2018 | 39.0 | -12.65% |
2017 | 44.6 | -19.6% |
2016 | 55.5 | 26.16% |
2015 | 44.0 |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.